Barclays PLC Purchases 202,248 Shares of ImmunityBio, Inc. (NASDAQ:IBRX)

Barclays PLC increased its position in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 127.4% during the 3rd quarter, Holdings Channel reports. The firm owned 361,036 shares of the company’s stock after acquiring an additional 202,248 shares during the period. Barclays PLC’s holdings in ImmunityBio were worth $1,344,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Captrust Financial Advisors purchased a new position in ImmunityBio in the 3rd quarter worth approximately $41,000. Algert Global LLC purchased a new stake in ImmunityBio during the 2nd quarter valued at approximately $86,000. Dimensional Fund Advisors LP bought a new stake in shares of ImmunityBio during the second quarter valued at approximately $105,000. CIBC Asset Management Inc purchased a new position in shares of ImmunityBio in the second quarter worth $118,000. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in ImmunityBio in the 2nd quarter worth $126,000. Hedge funds and other institutional investors own 8.58% of the company’s stock.

ImmunityBio Stock Performance

Shares of NASDAQ IBRX opened at $2.78 on Friday. ImmunityBio, Inc. has a 52-week low of $2.50 and a 52-week high of $10.53. The firm has a market capitalization of $1.94 billion, a price-to-earnings ratio of -3.02 and a beta of 0.86. The stock has a 50 day moving average price of $4.40 and a 200 day moving average price of $4.61.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. EF Hutton Acquisition Co. I raised ImmunityBio to a “strong-buy” rating in a research note on Wednesday, October 23rd. D. Boral Capital reaffirmed a “buy” rating and set a $30.00 price objective on shares of ImmunityBio in a report on Friday, December 20th.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.